Key Highlights
- GE HealthCare stock falls 13% after revised 2026 outlook.
- Q1 revenue reaches $5.1 billion, up 7.4% year-over-year.
- Supply chain pressures are expected to add approximately $250 million in costs.
Shares of GE HealthCare dropped sharply by 13% after the company reported first-quarter 2026 results alongside a reduced full-year earnings outlook. The stock closed at $59.49, down from $68.50 the previous day, reflecting investor concerns over rising costs and profitability pressures.
Despite delivering $5.1 billion in revenue, marking a 7.4% year-over-year increase, the company’s weaker profit expectations overshadowed its top-line growth.
Lowered 2026 Outlook Raises Concerns
GE HealthCare revised its full-year earnings forecast to $4.80-$5.00 per share, down from its earlier estimate of $4.95–$5.15. Expected annual growth has also been adjusted to 4.6%-9%, compared to the previously projected 7.9%-12.3% range.
The revised guidance reflects ongoing cost pressures that are expected to persist throughout 2026, prompting a cautious outlook from management.
Supply Chain Costs Weigh on Margins
CEO Peter Arduini attributed the weaker profitability to a combination of supply chain challenges and rising input costs. Although an issue with a pharmaceutical diagnostics supplier has been resolved, the company continues to face significant increases in key expense areas.
These include a projected $100 million increase in memory chip costs, as well as another $100 million in oil and freight expenses. Additional pressures from metal costs bring the total estimated impact to around $250 million, equivalent to approximately $0.43 per share.
Global Factors Add to Cost Pressures
The cost increases are partly linked to broader geopolitical developments, including disruptions stemming from tensions with Iran. The closure of the Strait of Hormuz has raised shipping costs globally, further straining supply chains and operational costs.
These external factors are expected to continue influencing expenses across the year, adding uncertainty to the company’s financial outlook.
Business Segments Show Mixed Performance
GE HealthCare’s imaging segment remained its largest revenue contributor, generating approximately $2.3 billion, up 7.4% year-over-year. The Advanced Visualization Solutions (AVS) segment followed, reporting revenue of around $1.34 billion, up 8.2%.
Meanwhile, the pharmaceutical diagnostics segment posted the strongest growth, rising 21.7% year over year to $770 million, despite earlier supply-related challenges.
While GE HealthCare aims to offset more than half of the inflationary impact through pricing and cost-control measures, investor sentiment remains cautious.
The company emphasized ongoing innovation efforts to support long-term growth, but near-term performance will likely depend on how effectively it manages supply chain pressures and rising input costs.